Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong-Yu Liu

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Biorxiv : the Preprint Server for Biology|November 24, 2025
Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harbor Homozygous p53 MutantsMd Saqline Mostaq, Mohammad N Amin, Amanda Raphael, et al.
Molecular Cancer|June 15, 2010
Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signalingYong-Yu Liu, Vineet Gupta, Gauri A Patwardhan, et al.
FASEB Bioadvances|November 18, 2020
Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylationKartik R Roy, Mohammad B Uddin, Sagor C Roy, et al.
International Journal of Molecular Sciences|April 14, 2026
Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 MutantsMd Saqline Mostaq, Mohammad N Amin, Amanda Raphael, et al.
Biochemical Pharmacology|December 23, 2018
An N<sup>6</sup>-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cellsMohammad B Uddin, Kartik R Roy, Salman B Hosain, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 5, 2008
In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicityXiao-Lin Li, Dong-Qing Zhang, David Wang, et al.
Molecular Cancer Therapeutics|May 14, 2004
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapyValerie Gouazé, Jing Y Yu, Richard J Bleicher, et al.
Biochemical Pharmacology|April 14, 2010
Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approachesJacqueline V Chapman, Valérie Gouazé-Andersson, Maria C Messner, et al.
Plos One|September 11, 2009
A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosisGauri A Patwardhan, Qian-Jin Zhang, Dongmei Yin, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 5, 2008
A role for ceramide in driving cancer cell resistance to doxorubicinYong-Yu Liu, Jing Yuan Yu, Dongmei Yin, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Biorxiv : the Preprint Server for Biology|November 24, 2025
Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harbor Homozygous p53 MutantsMd Saqline Mostaq, Mohammad N Amin, Amanda Raphael, et al.
Molecular Cancer|June 15, 2010
Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signalingYong-Yu Liu, Vineet Gupta, Gauri A Patwardhan, et al.
FASEB Bioadvances|November 18, 2020
Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylationKartik R Roy, Mohammad B Uddin, Sagor C Roy, et al.
International Journal of Molecular Sciences|April 14, 2026
Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 MutantsMd Saqline Mostaq, Mohammad N Amin, Amanda Raphael, et al.
Biochemical Pharmacology|December 23, 2018
An N<sup>6</sup>-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cellsMohammad B Uddin, Kartik R Roy, Salman B Hosain, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 5, 2008
In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicityXiao-Lin Li, Dong-Qing Zhang, David Wang, et al.
Molecular Cancer Therapeutics|May 14, 2004
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapyValerie Gouazé, Jing Y Yu, Richard J Bleicher, et al.
Biochemical Pharmacology|April 14, 2010
Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approachesJacqueline V Chapman, Valérie Gouazé-Andersson, Maria C Messner, et al.
Plos One|September 11, 2009
A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosisGauri A Patwardhan, Qian-Jin Zhang, Dongmei Yin, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 5, 2008
A role for ceramide in driving cancer cell resistance to doxorubicinYong-Yu Liu, Jing Yuan Yu, Dongmei Yin, et al.
Pageof 7